Drugs / tegafur/uracil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00464919 | Apr 2007 → Mar 2009 | hepatocellular carcinoma | National Taiwan University Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tegafur/uracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00464919 ↗ |
| Known as | UFUR | “UFUR®, a composite drug composed of tegafur and uracil, is an orally active 5-fluorouracil (5-FU) preparation.” NCT00464919 ↗ |
| Route | Oral | “UFUR®, a composite drug composed of tegafur and uracil, is an orally active 5-fluorouracil (5-FU) preparation.” NCT00464919 ↗ |